Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [2707]

Alpelisib and fulvestrant for advanced breast cancer: SOLAR-1

Prof Fabrice André - Institut Gustave Roussy, Paris, France

Alpelisib and fulvestrant for advanced breast cancer: SOLAR-1 ( Prof Fabrice André - Institut Gustave Roussy, Paris, France )

Results from the IMpassion130 trial for triple-negative breast cancer

Prof Peter Schmid - St Bartholomew Hospital London, UK

Results from the IMpassion130 trial for triple-negative breast cancer ( Prof Peter Schmid - St Bartholomew Hospital London, UK )

PALOMA-3 update, including OS data for HR positive HER2 negative breast cancer

Prof Massimo Cristofanilli - Feinberg School of Medicine, Chicago, USA

PALOMA-3 update, including OS data for HR positive HER2 negative breast cancer ( Prof Massimo Cristofanilli - Feinberg School of Medicine, Chicago, USA )

Results from the PALOMA-3 trial for advanced breast cancer

Prof Massimo Cristofanilli - Feinberg School of Medicine, Chicago, USA

Results from the PALOMA-3 trial for advanced breast cancer ( Prof Massimo Cristofanilli - Feinberg School of Medicine, Chicago, USA )

Immunological monitoring of patients receiving immunotherapy

Prof Jaques van Dongen - Leiden University, Netherlands

Immunological monitoring of patients receiving immunotherapy ( Prof Jaques van Dongen - Leiden University, Netherlands )

Combining MRD quantitation and genetics in post-remission risk stratification

Dr John Moppett - University Hospitals Bristol NHS Foundation Trust, Bristol, UK

Combining MRD quantitation and genetics in post-remission risk stratification ( Dr John Moppett - University Hospitals Bristol NHS Foundation Trust, Bristol, UK )

Management of MLL-rearranged ALL

Prof Rob Pieters - Princess Maxima Centre for paediatric oncology (UU), Utrecht...

Management of MLL-rearranged ALL ( Prof Rob Pieters - Princess Maxima Centre for paediatric oncology (UU), Utrecht, Netherlands )

Editor’s Choice for September 2018

Prof Gordon McVie - Founding Editor, ecancer

Editor’s Choice for September 2018 ( Prof Gordon McVie - Founding Editor, ecancer )

The microbiome – a novel paradigm in oncology research

Dr Alasdair Scott - Imperial College London, London, UK

The microbiome – a novel paradigm in oncology research ( Dr Alasdair Scott - Imperial College London, London, UK )

Editor's Choice for August 2018

Prof Gordon McVie - Founding Editor, ecancer

Editor's Choice for August 2018 ( Prof Gordon McVie - Founding Editor, ecancer )

Updates from a range of lung cancer studies

Prof Edgardo S. Santos - Lynn Cancer Institute, Boca Raton, USA

Updates from a range of lung cancer studies ( Prof Edgardo S. Santos - Lynn Cancer Institute, Boca Raton, USA )

Large B-cell lymphoma: ZUMA-1 trial

Dr Frederick Locke - Moffitt Cancer Center, Tampa, USA

Large B-cell lymphoma: ZUMA-1 trial ( Dr Frederick Locke - Moffitt Cancer Center, Tampa, USA )

More from ecancer